ClinicalTrials.gg
RecruitingNCT06422923Updated Jan 7, 2026

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

A Phase 1/2 interventional study of NRTX-1001 in Epilepsy, Temporal Lobe, sponsored by Neurona Therapeutics. Recruiting at 17 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Neurona Therapeutics (part of UCB S.A.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies in Epilepsy, Temporal Lobe with a site in United States — 10 open to participants now, 10 under way, none of them phase 3. Epilepsy, Temporal Lobe · United States.

Planned enrollment
10th of 19
10 · median 10
Started
2024
with 2 others
Phase 1/2
Only one
of the 30
Registered
27th of 30
by date
Lead sponsor
1 of 30
Neurona Therapeutics

Among the 30 studies in Epilepsy, Temporal Lobe with a site in United States, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 1/2, and was the 27th registered.

Epilepsy, Temporal Lobe

65 studies on the registry are indexed under Epilepsy, Temporal Lobe; 25 are open to participants now.

Browse Epilepsy, Temporal Lobe studies →

Open to participants now

10 of the 30 studies in Epilepsy, Temporal Lobe with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Epilepsy, Temporal Lobe studies recruiting now, 6 (32%) set no upper age limit and 9 (47%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Epilepsy, Temporal Lobe with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes of subjects with drug-resistant bilateral mesial temporal lobe epilepsy.

Read the detailed description

This is a multicenter, single arm, open-label study of NRTX-1001 in subjects with drug-resistant bilateral MTLE, with the objective of evaluating safety and preliminary efficacy in reducing seizure frequency. The subjects will undergo a single stereotactic CT or MRI-guided intracerebral administration of human interneurons into both temporal lobe regions of the brain. NRTX-1001 secretes the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is intended to suppress the onset and spread of the seizures. Safety, tolerability, and effects on epilepsy disease symptoms will be assessed at approximately quarterly intervals for 2 years after the administration of NRTX-1001. After the two-year period, subjects will be followed with quarterly phone calls and annual visits in years 3 through 15.

03

Conditions studied

  • Epilepsy, Temporal Lobe

Keywords

  • Bilateral Temporal Lobe Epilepsy
  • Bilateral MTLE
  • Refractory Bilateral MTLE
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female, age 18-75 years.
  2. Subjects of will use highly effective .
  3. Proven history of focal seizures of hippocampal origin with bilateral seizure foci confirmed by scalp or intracranial ictal EEG (including confirmation by recordings from responsive neurostimulation [RNS] electrodes when applicable).
  4. Either

    1. bilateral hippocampal sclerosis on MRI (evidenced by increased FLAIR signal intensity in both hippocampi or by visual assessment showing reduced volume compared to normal) or
    2. bilateral temporal hypometabolism on 18-Flourodeoxyglucose Positron Emission Tomography (FDG PET) (assessed by visual assessment, comparing temporal regions to frontal/parietal lobe neocortex). In this case, ictal EEG recordings must also include intracranial confirmation.

      or

    3. a combination of unilateral instances of the evidence described in a. and b. (e.g., one side can be evidenced by criterion a. and the other side by criterion b.) MRI or PET scans used for assessment must have been acquired within 3 years of screening.
  5. Subject has had at least four clinical focal seizures, including at least two clinical focal seizures with objective manifestations, on average, per month for the 6 months prior to screening.
  6. Subject has previously had adequate (in opinion of investigator) therapeutic trials of at least two Anti-Seizure Medicines (ASMs).
  7. Current ASM regimen, and doses of other drugs known to affect seizure frequency (e.g., antidepressants), have been stable for at least three months prior to enrollment.
  8. Subject can converse and read in English or Spanish. Able to participate in required study procedures and provide signed .

Key Exclusion Criteria:

  1. Epilepsy due to other and/or progressive neurologic disease.
  2. Evidence of seizure focus outside hippocampus (either by seizure semiology or EEG findings).
  3. MRI indicating potential malignant lesion (low-grade glioma of any type is excluded) in any location or non-malignant potentially epileptogenic lesion outside the hippocampus. Small (\<2 cm) non invasive meningioma, remote from the affected temporal lobe, is not exclusionary.
  4. Seizures of non-focal origin.
  5. History of status epilepticus in the year prior to screening, as guided by ILAE criteria (Trinka 2015) in the judgement of the PI. A history of cluster seizures is permitted.
  6. Psychogenic Non-Epileptic Seizures (PNES) within the past 3 years.
  7. Severe psychiatric disorders.
  8. Primary or secondary immunodeficiency.
  9. Pregnancy, or currently breastfeeding.
  10. Suicide attempts in past year.
  11. Significant other medical conditions which would impair safe participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    This is an open-label study of the bilateral intrahippocampal administration of NRTX-1001 in a single dose cohort of up to 10 subjects with drug-resistant bilateral MTLE.

    Biological: NRTX-1001

Interventions

  • BiologicalNRTX-1001

    Biological: NRTX-1001 is an inhibitory neural cell therapy investigational product. It is derived from a human stem cell line that has been converted into high-purity inhibitory interneurons that produce GABA. NRTX-1001 is intended to persist long-term and not require repeated administration.

    Also known as: GABA-secreting interneurons

06

What researchers measure

Primary outcomes

  1. Incidence of Serious Adverse Events at end of month 12

    Time frame: 12 months after treatment

Secondary outcomes

  1. Change in frequency of clinical seizures

    Seizure frequency change during months 7-12, compared to frequency of clinical seizures in the 6-month baseline period.

    Time frame: 12 months after treatment

07

Study locations

16 of 17 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 21, 2024
StartActual
Nov 14, 2024
Primary completionEst.
Jun 15, 2027
CompletionEst.
Jun 15, 2042
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06422923
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Nov 14, 2024
Primary completion
Jun 15, 2027 (estimated)
Completion
Jun 15, 2042 (estimated)
Last update
Jan 7, 2026

Study contacts

Neurona MedInfo
Contact
neuronamedinfo@neuronatx.com
650-580-3825
Eduardo Dunayevich, MD
Contact
edunayevich@neuronatx.com
650-436-3045
Eduardo Dunayevich, MD
study director · Neurona Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion